|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KRI1 |
Gene summary for KRI1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KRI1 | Gene ID | 65095 |
| Gene name | KRI1 homolog | |
| Gene Alias | KRI1 | |
| Cytomap | 19p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000447 | UniProtAcc | Q8N9T8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65095 | KRI1 | LZE2T | Human | Esophagus | ESCC | 1.38e-02 | 4.31e-01 | 0.082 |
| 65095 | KRI1 | LZE4T | Human | Esophagus | ESCC | 1.46e-14 | 4.39e-01 | 0.0811 |
| 65095 | KRI1 | LZE7T | Human | Esophagus | ESCC | 2.46e-11 | 5.90e-01 | 0.0667 |
| 65095 | KRI1 | LZE8T | Human | Esophagus | ESCC | 1.29e-08 | 2.83e-01 | 0.067 |
| 65095 | KRI1 | LZE20T | Human | Esophagus | ESCC | 2.22e-04 | 8.11e-02 | 0.0662 |
| 65095 | KRI1 | LZE24T | Human | Esophagus | ESCC | 1.21e-16 | 4.45e-01 | 0.0596 |
| 65095 | KRI1 | LZE21T | Human | Esophagus | ESCC | 2.00e-07 | 4.45e-01 | 0.0655 |
| 65095 | KRI1 | LZE6T | Human | Esophagus | ESCC | 3.81e-04 | 1.52e-01 | 0.0845 |
| 65095 | KRI1 | P1T-E | Human | Esophagus | ESCC | 5.99e-10 | 6.80e-01 | 0.0875 |
| 65095 | KRI1 | P2T-E | Human | Esophagus | ESCC | 1.50e-16 | 3.40e-01 | 0.1177 |
| 65095 | KRI1 | P4T-E | Human | Esophagus | ESCC | 6.97e-30 | 6.72e-01 | 0.1323 |
| 65095 | KRI1 | P5T-E | Human | Esophagus | ESCC | 1.25e-17 | 3.60e-01 | 0.1327 |
| 65095 | KRI1 | P8T-E | Human | Esophagus | ESCC | 5.82e-29 | 5.11e-01 | 0.0889 |
| 65095 | KRI1 | P9T-E | Human | Esophagus | ESCC | 1.46e-27 | 6.37e-01 | 0.1131 |
| 65095 | KRI1 | P10T-E | Human | Esophagus | ESCC | 3.56e-33 | 5.93e-01 | 0.116 |
| 65095 | KRI1 | P11T-E | Human | Esophagus | ESCC | 2.95e-06 | 2.79e-01 | 0.1426 |
| 65095 | KRI1 | P12T-E | Human | Esophagus | ESCC | 8.46e-41 | 7.44e-01 | 0.1122 |
| 65095 | KRI1 | P15T-E | Human | Esophagus | ESCC | 6.50e-21 | 5.08e-01 | 0.1149 |
| 65095 | KRI1 | P16T-E | Human | Esophagus | ESCC | 3.61e-22 | 2.82e-01 | 0.1153 |
| 65095 | KRI1 | P17T-E | Human | Esophagus | ESCC | 4.35e-13 | 4.26e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000047911 | Thyroid | ATC | endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 11/6293 | 15/18723 | 1.94e-03 | 9.41e-03 | 11 |
| GO:000046611 | Thyroid | ATC | maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 15/6293 | 24/18723 | 3.52e-03 | 1.56e-02 | 15 |
| GO:009030511 | Thyroid | ATC | nucleic acid phosphodiester bond hydrolysis | 107/6293 | 261/18723 | 7.21e-03 | 2.84e-02 | 107 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KRI1 | SNV | Missense_Mutation | rs752490810 | c.971C>T | p.Ala324Val | p.A324V | Q8N9T8 | protein_coding | tolerated(0.08) | benign(0.099) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KRI1 | SNV | Missense_Mutation | c.193G>A | p.Asp65Asn | p.D65N | Q8N9T8 | protein_coding | tolerated(0.09) | probably_damaging(0.996) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
| KRI1 | SNV | Missense_Mutation | novel | c.1366C>G | p.Pro456Ala | p.P456A | Q8N9T8 | protein_coding | tolerated(0.07) | possibly_damaging(0.76) | TCGA-B6-A0I1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| KRI1 | SNV | Missense_Mutation | c.1316N>A | p.Gly439Glu | p.G439E | Q8N9T8 | protein_coding | deleterious(0.04) | probably_damaging(0.959) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KRI1 | insertion | Nonsense_Mutation | novel | c.1555_1556insCTAATAGTCCTAATGACAGTGCTAATAACATTACCTCGCCTCAAAGGT | p.Glu519delinsAlaAsnSerProAsnAspSerAlaAsnAsnIleThrSerProGlnArgTer | p.E519delinsANSPNDSANNITSPQR* | Q8N9T8 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| KRI1 | deletion | Frame_Shift_Del | novel | c.792delN | p.Asp264GlufsTer31 | p.D264Efs*31 | Q8N9T8 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| KRI1 | SNV | Missense_Mutation | c.1465N>A | p.Ala489Thr | p.A489T | Q8N9T8 | protein_coding | tolerated(0.06) | probably_damaging(0.956) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| KRI1 | SNV | Missense_Mutation | novel | c.1363N>A | p.Asp455Asn | p.D455N | Q8N9T8 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| KRI1 | SNV | Missense_Mutation | c.1801G>A | p.Ala601Thr | p.A601T | Q8N9T8 | protein_coding | tolerated(0.72) | benign(0) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| KRI1 | SNV | Missense_Mutation | rs150288571 | c.1291G>A | p.Asp431Asn | p.D431N | Q8N9T8 | protein_coding | tolerated(0.2) | benign(0.02) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |